Printer Friendly

Statins after prostate cancer dx may reduce deaths.

The use of statins following a prostate cancer diagnosis was associated with a decrease in all-cause and prostate cancer--related mortality risks in a large cohort of men from the United Kingdom.

The risk reduction was greatest among those who also used statins prior to their diagnosis, said Dr. Oriana Yu, of Jewish General Hospital, Montreal, and her colleagues.

The findings support experimental evidence suggesting an antitumor effect of statins on prostate carcinogenesis. Additional observational studies are needed to confirm the findings before a randomized controlled trial is launched to assess the effects of statins in the adjuvant setting, they said.

The study subjects were 11,722 men (mean age, 71.3 years) who were retrospectively identified from a large population-based electronic database. All were newly diagnosed as having nonmetastatic prostate cancer between April 1, 1998, and Dec. 31, 2009. During a mean follow-up of 4.4 years, 3,499 died, including 1,791 who died from prostate cancer.

Those who used statins after their prostate cancer diagnosis had a 24% decrease in the risk of prostate cancer mortality (hazard ratio, 0.76), and a 14% decrease in the risk of all-cause mortality (HR, 0.86). Statin use post diagnosis also was associated with a decreased risk of distant metastasis (HR, 0.77).

Among those who also used statins prior to their diagnosis, the corresponding hazard ratios for prostate cancer--related and all-cause mortalities were 0.55 and 0.66, compared with 0.82 and 0.91, respectively, for those who used statins only after diagnosis, the researchers reported (J. Clin Oncol. 2014; 32:5-11).

"A dose-response relationship was observed in terms of cumulative duration of use and dose, with the HRs becoming progressively more protective with longer durations of use and higher cumulative doses," they wrote.

For example, the adjusted hazard ratios for those using statins for less than 1 year and for those using statins for 3 or more years were 0.99 and 0.61, respectively. The adjusted hazard ratios for cumulative doses of less than 365 mg and 1,096 mg or more were 0.84 and 0.57, respectively.

Accumulating evidence suggests that statins have antitumor effects. Observational studies have looked at the association between statin use and prostate cancer outcomes, but the findings have been inconsistent, and none have specifically assessed whether prediagnosis use of statins modified the association seen between postdiagnosis use and outcomes, the investigators said.

The findings of an effect modification by prediagnostic use of statins in this study could be explained by several factors. First, tumor characteristics may be more favorable in those using statins before diagnosis, resulting in improved prostate cancer outcomes, the investigators said.

Second, duration of statin use is longest among those who used statins before their diagnosis.

Finally, men who start statins before their prostate cancer diagnosis may differ from those who start after diagnosis. "Specifically, it is possible that the latter group required statins as a consequence of certain treatment, such as androgen deprivation therapy, which is known to increase lipid levels," they noted.

The Canadian Institutes of Health Research supported this study. Dr. Yu reported having no disclosures. One of her coauthors, Samy Suissa, Ph.D., reported serving as a consultant or adviser for AstraZeneca, Boehringer Ingelheim, and other companies.

BY SHARON WORCESTER FROM THE JOURNAL OF CLINICAL ONCOLOGY
COPYRIGHT 2014 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Worcester, Sharon
Publication:Internal Medicine News
Date:Feb 1, 2014
Words:553
Previous Article:Medicare takes aim at 'abusive' prescribing.
Next Article:Findings may prompt more statin use.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters